Actively Recruiting
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Led by University of Chicago · Updated on 2026-01-14
1200
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
CONDITIONS
Official Title
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
You will not qualify if you...
- Under 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
O
Omar Jamil, MD
CONTACT
M
Maria Newsome
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here